Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Construction in Progress: 2011-2016

  • Anika Therapeutics' Construction in Progress rose 101.30% to $22.7 million in Q4 2016 from the same period last year, while for Dec 2016 it was $22.7 million, marking a year-over-year increase of 101.30%. This contributed to the annual value of $22.7 million for FY2016, which is 101.30% up from last year.
  • Latest data reveals that Anika Therapeutics reported Construction in Progress of $22.7 million as of Q4 2016, which was up 101.30% from $11.3 million recorded in Q4 2015.
  • Anika Therapeutics' 5-year Construction in Progress high stood at $22.7 million for Q4 2016, and its period low was $42,270 during Q4 2012.
  • For the 3-year period, Anika Therapeutics' Construction in Progress averaged around $11.5 million, with its median value being $11.3 million (2015).
  • Per our database at Business Quant, Anika Therapeutics' Construction in Progress slumped by 99.84% in 2012 and then soared by 1,916.82% in 2015.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Construction in Progress stood at $42,270 in 2012, then skyrocketed by 272.11% to $157,292 in 2013, then skyrocketed by 255.39% to $559,000 in 2014, then soared by 1,916.82% to $11.3 million in 2015, then soared by 101.30% to $22.7 million in 2016.
  • Its Construction in Progress stands at $22.7 million for Q4 2016, versus $11.3 million for Q4 2015 and $559,000 for Q4 2014.